InMed Pharmaceuticals Inc (INM) Stock Price Fluctuations: Highs and Lows

In the latest session, InMed Pharmaceuticals Inc (NASDAQ: INM) closed at $0.36 up 4.96% from its previous closing price of $0.35. In other words, the price has increased by $+0.0320 from its previous closing price. On the day, 59806 shares were traded.

Ratios:

For a deeper understanding of InMed Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.58 and its Current Ratio is at 7.03. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 21 ’24 when HULL ANDREW bought 37,500 shares for $0.39 per share. The transaction valued at 14,625 led to the insider holds 38,258 shares of the business.

ADAMS ERIC A bought 41,600 shares of INM for $14,922 on Feb 20 ’24. The President & CEO now owns 43,959 shares after completing the transaction at $0.36 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INM now has a Market Capitalization of 2.10M and an Enterprise Value of -6.27M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.22 while its Price-to-Book (P/B) ratio in mrq is 0.16. Its current Enterprise Value per Revenue stands at -1.14 whereas that against EBITDA is 0.98.

Stock Price History:

Over the past 52 weeks, INM has reached a high of $2.08, while it has fallen to a 52-week low of $0.29. The 50-Day Moving Average of the stock is 0.3644, while the 200-Day Moving Average is calculated to be 0.6271.

Shares Statistics:

For the past three months, INM has traded an average of 168.92K shares per day and 61.83k over the past ten days. A total of 3.33M shares are outstanding, with a floating share count of 3.28M. Insiders hold about 1.56% of the company’s shares, while institutions hold 24.16% stake in the company. Shares short for INM as of Mar 15, 2024 were 56.97k with a Short Ratio of 0.34, compared to 138.25k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.94% and a Short% of Float of 0.94%.

Earnings Estimates

There are 0 different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.

Revenue Estimates

A total of 1 analysts believe the company’s revenue will be $1.49M this quarter.It ranges from a high estimate of $1.49M to a low estimate of $1.49M. As of the current estimate, InMed Pharmaceuticals Inc’s year-ago sales were $1.03M, an estimated increase of 44.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $1.79M, a decrease of -22.60% less than the figure of $44.10% in the same quarter last year. There is a high estimate of $1.79M for the next quarter, whereas the lowest estimate is $1.79M.

A total of 1 analysts have provided revenue estimates for INM’s current fiscal year. The highest revenue estimate was $5.42M, while the lowest revenue estimate was $5.42M, resulting in an average revenue estimate of $5.42M. In the same quarter a year ago, actual revenue was $4.14M, up 31.00% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $6.77M in the next fiscal year. The high estimate is $6.77M and the low estimate is $6.77M. The average revenue growth estimate for next year is up 24.90% from the average revenue estimate for this year.

Most Popular